Prevention of nosocomial bacterial pneumonia

Vincent, Jean‐Louis

doi:10.1136/thx.54.6.544

Cited by 31 publications

(20 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The reason for this misconception is multi-factorial. However, the longstanding disagreement amongst experts [85,86] has been an important factor contributing to the confusion. History repeats itself in that Semmelweis' work was heavily opposed by Virchow, the expert pathologist of that time [87].…”

Section: Treatment Of Pneumonia and Septicaemiamentioning

confidence: 99%

“…As opinion leaders control the media, SDD has, since its launch, received unfair and unfavourable criticism [47,85,86,89,90,92,95]. For example, SDD has been a regular feature on the programme of the annual Intensive Care meeting in Brussels, Belgium, though since 1984, apart from 2 years in 1988 and 1990, speakers invited to discuss SDD were selected from a group of experts who openly opposed SDD.…”

Section: Treatment Of Pneumonia and Septicaemiamentioning

confidence: 99%

See 1 more Smart Citation

All great truths are iconoclastic: selective decontamination of the digestive tract moves from heresy to level 1 truth

et al. 2003

View full text Add to dashboard Cite

show abstract

Section: Treatment Of Pneumonia and Septicaemiamentioning

confidence: 99%

Section: Treatment Of Pneumonia and Septicaemiamentioning

confidence: 99%

All great truths are iconoclastic: selective decontamination of the digestive tract moves from heresy to level 1 truth

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Endotrakeal entübasyon sırasında pnömoni tablosu veya pnö-moni gelişmekte olduğunu destekleyen klinik bulgusu olmayan hastada invaziv mekanik ventilatör desteğinden en az 48 saat sonra gelişen pnömoniler ventilatör ilişkili pnömoni(VİP) olarak kabul edilir [1]. VİP, mekanik ventilasyon (MV) desteği alan hastaların %8-28'inde gelişen ve mortalite oranı %27-76'ya dek yük-selebilen ciddi bir komplikasyondur [2].…”

Section: Introductionunclassified

Analyze of Ventilator Associated Pneumonia

Sünnetçioğlu¹

2015

Ann Clin Anal Med

View full text Add to dashboard Cite

Anahtar KelimelerVentilatör İlişkili Pnömoni; Etkenler; Antibiyotik Duyarlılığı Abstract Aim: Ventilator-associated pneumonia (VAP) is the infection that is an important cause of morbidity and mortality developed in patients whom the invasive mechanical ventilation (MV) were performed in intensive care units (ICU). In this study, the factors of VAP developing in patients whom the mechanical ventilation of ICU performed, antibiotic susceptibility to these factors and determining the risk factors were aimed. Material and Method: Between January 2009 and March 2013, 79 cases, followed with the mechanical ventilation for at least for 48 hours and developed VAP, were retrospectively reviewed at Anesthesiology and Intensive Care Unit of Reanimation at Faculty of Medicine at Yuzuncu Yil University, performing endotracheal intubation. The cases were evaluated in terms of microorganisms, antibiotic susceptibility and risk factors. Results: The rate of our VAP speed was calculated to be 19.68 on the day of 1000 ventilator. While a single microorganism could be isolated in 81.1% of the 74 VAP cases whose the active pathogen could be isolated, two or more than two microorganisms were isolated in 18.9% of them.While 83 of the strains (90.2%) were gram-negative bacteria, 7 of them (7.6%) were gram-positive bacteria. Acinetobacter spp. (40.2%) was most commonly isolated as a gram-negative factor, but methicillin-resistant S. aureus (4.3%) was isolated as a gram-positive factor. It was determined that the isolated factors in VAP cases were significantly resistant to the broadspectrum antibiotics. Discussion: As a result, in patients with high-risk factors for the development of VAP, early and appropriate empirical antibiotic treatment should be started according to the results of the sensitivity of the unit and for the multi-drug-resistant microorganisms with common and high mortality.

show abstract

“…It is clear that for SDD certain populations may benefit: surgical rather than medical patients and those who are immunosuppressed or are undergoing liver transplant and oesophagectomy (Vincent 1999). Gorman et al (1993) and Adair et al (1993) demonstrated that SDD did not have any effect on reducing VAP-causing pathogens.…”

Section: Selective Decontamination Of the Digestive Tract (Sdd)mentioning

confidence: 99%

Pharmaceutical strategies to prevent ventilator-associated pneumonia

McCrory

Jones

Adair

et al. 2003

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

The increasing incidence of hospital-acquired (nosocomial) infection is a disturbing phenomenon resulting in significant patient mortality and putting considerable strain on healthcare budgets and personnel. One particularly serious aspect of nosocomial infection is that of ventilator-associated pneumonia (VAP). This arises in patients who receive mechanical ventilation within the intensive care unit. The quoted incidence of VAP varies widely (5-67%) and the reported mortality of patients with VAP is in the range of 24-71%. This review will examine the many factors that account for these wide ranges reported, including the patient population under investigation, the causative organism, the method of diagnosis, interventions employed and preventative strategies. The use of bioactive and drug-impregnated biomaterials for endotracheal tube construction is discussed as novel approaches to the prevention of VAP.

show abstract

Prevention of nosocomial bacterial pneumonia

Cited by 31 publications

References 80 publications

All great truths are iconoclastic: selective decontamination of the digestive tract moves from heresy to level 1 truth

All great truths are iconoclastic: selective decontamination of the digestive tract moves from heresy to level 1 truth

Analyze of Ventilator Associated Pneumonia

Pharmaceutical strategies to prevent ventilator-associated pneumonia

Contact Info

Product

Resources

About